Allergan plc (AGN): Incrementally Cautious - Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Mizuho Securities Remains Sidelined on Allergan (AGN) following 1Q Earnings; PT to $232
May 13, 2016 6:52 AM EDTMizuho Securities maintained a Neutral rating on Allergen (NYSE: AGN), and cut the price target to $232.00 (from $250.00), following the company's 1Q earnings report. AGN reported $3.8B in revenues and EPS of $3.04 vs. consensus estimates $3.95B and $3.00. Management reiterated its FY16 revenue guidance of... More
Allergan profit beats estimates, share buybacks planned
May 10, 2016 7:48 AM EDTBy Amrutha Penumudi and Ransdell Pierson
(Reuters) - Allergan Plc (NYSE: AGN), whose $160 billion merger with Pfizer Inc (NYSE: PFE) collapsed last month, reported a higher-than-expected quarterly profit and said it would buy back up to $10 billion in company stock, helping lift its shares 4 percent.
The Dublin drugmaker on Tuesday said the planned $40 billion sale of its generics business to Teva Pharmaceutical Industries (NYSE: TEVA) will close next month and that it will use $8 billion of the money to pay down... More
Allergan (AGN) Tops Q1 EPS by 1c
May 10, 2016 7:31 AM EDTAllergan (NYSE: AGN) reported Q1 EPS of $3.04, $0.01 better than the analyst estimate of $3.03. Revenue for the quarter came in at $3.8 billion versus the consensus estimate of $3.96 billion.
Allergan's full year 2016 continuing operations standalone estimates are based on management's current belief about prescription trends,... More
